<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771991</url>
  </required_header>
  <id_info>
    <org_study_id>SOD 2012</org_study_id>
    <nct_id>NCT01771991</nct_id>
  </id_info>
  <brief_title>Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis</brief_title>
  <acronym>Sodermix</acronym>
  <official_title>Topical Superoxide Dismutase For the Treatment of Radiation Induced Fibrosis in the Head and Neck Cancer Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanford Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanford Health</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if topical superoxide dismutase is an effective
      treatment of radiation related neck fibrosis, and to determine the quality of life impact
      from radiation related fibrosis in the head and neck cancer patients at Sanford Health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this study is to evaluate the effect of topical Superoxide Dismutase
      (SOD) on the radiation induced fibrosis in head and neck cancer patients. A prospective,
      blinded, two group control design will be used with pretest and post test quality of life as
      well as objective fibrosis assessment. Patients will be randomized to alternatively receive
      topical SOD or placebo as instructed on twice daily use for 3 months. Pre and post treatment
      quality of life surveys and objective assessment will determine if the topical SOD improves
      neck fibrosis/function and global quality of life.

      This study will increase clinical trial awareness and participation while potentially
      improving the long term functional outcomes of head and neck cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Neck Fibrosis</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in fibrosis as defined as a one point improvement on the fibrosis scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Quality of Life Impact From Radiation Related Fibrosis in Head and Neck Cancer Patients</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Metrics are measured via analysis of pain and range of motion and Health Related Quality of Life questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Radiation Induced Fibrosis to the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Topical Sodermix Dismutase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to Topical Sodermix Dismutase in the form of Sodermix(SOD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cetaphil cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Sodermix Dismutase in the form of Sodermix (SOD)</intervention_name>
    <description>Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.</description>
    <arm_group_label>Topical Sodermix Dismutase</arm_group_label>
    <other_name>Sodermix</other_name>
    <other_name>SOD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Cetaphil cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have evidence of neck fibrosis

          -  previous radiation treatment to the neck for cancer

          -  age greater than or equal to 18 years

          -  life expectancy of greater than 12 weeks

          -  ability to understand the purpose of the study and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to SOD or Cetaphil cram.

          -  any psychological, familial, sociological or geographical conditions that do not
             permit medical follow-up and compliance with the study protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William C Spanos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanford Health/Sanford Clinic ENT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 9, 2015</lastchanged_date>
  <firstreceived_date>January 11, 2013</firstreceived_date>
  <firstreceived_results_date>April 9, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrosis</keyword>
  <keyword>radiation</keyword>
  <keyword>neck</keyword>
  <keyword>cancer</keyword>
  <keyword>Sodermix</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Superoxide Dismutase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topical Sodermix Dismutase</title>
          <description>Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to Topical Sodermix Dismutase in the form of Sodermix(SOD)
Topical Sodermix Dismutase in the form of Sodermix (SOD): Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Cetaphil cream
Placebo: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Sodermix Dismutase</title>
          <description>Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to Topical Sodermix Dismutase in the form of Sodermix(SOD)
Topical Sodermix Dismutase in the form of Sodermix (SOD): Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Cetaphil cream
Placebo: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.98" spread="9.64"/>
                <measurement group_id="B2" value="61.64" spread="9.73"/>
                <measurement group_id="B3" value="61.3" spread="9.62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="59"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Neck Fibrosis</title>
        <description>Improvement in fibrosis as defined as a one point improvement on the fibrosis scale.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Topical Sodermix Dismutase</title>
            <description>Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to Topical Sodermix Dismutase in the form of Sodermix(SOD)
Topical Sodermix Dismutase in the form of Sodermix (SOD): Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Cetaphil cream
Placebo: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Improvement in Neck Fibrosis</title>
            <description>Improvement in fibrosis as defined as a one point improvement on the fibrosis scale.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Quality of Life Impact From Radiation Related Fibrosis in Head and Neck Cancer Patients</title>
        <description>Metrics are measured via analysis of pain and range of motion and Health Related Quality of Life questionnaire.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topical Sodermix Dismutase</title>
          <description>Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to Topical Sodermix Dismutase in the form of Sodermix(SOD)
Topical Sodermix Dismutase in the form of Sodermix (SOD): Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Cetaphil cream
Placebo: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The # of patients reported as &quot;complete&quot; finished the entire study, including 3 mo post-treatment follow-up. Pts who did not complete the follow-up visit, but did complete treatment are listed as &quot;completed treatment&quot; and were considered evaluable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Chad Spanos MD</name_or_title>
      <organization>Sanford Health</organization>
      <phone>605-328-8200</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
